Xtandi Makes Strong Contribution to Astellas’s Half-Year Sales and Profits

Astellas Pharma reported strong growth in April-September in both sales and profits due mainly to growth in sales of products including the prostate cancer treatment Xtandi (enzalutamide) and its line of overactive bladder (OAB) treatments. An increase in gross profits...read more